Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
The long-term extension of the
As previously reported, in the initial 12-week portion of this study, baricitinib was associated with statistically significant improvements in the signs and symptoms of RA disease versus placebo[1] and these responses were maintained or improved during an additional 12 weeks of blinded treatment.[2]
In the long-term extension, the clinical improvements observed at week 24 were sustained through 52 weeks in RA patients. The following chart summarizes selected efficacy results:
Disease |
24-Week Responders/Total |
52-Week Responders/Total |
ACR20 |
149/201 (74%) |
139/196 (71%) |
ACR50 |
83/201 (41%) |
96/197 (49%) |
ACR70 |
43/201 (21%) |
53/197 (27%) |
CDAI Remission |
34/200 (17%) |
40/195 (21%) |
SDAI Remission |
30/195 (15%) |
42/194 (22%) |
DAS28 ESR < 2.6 |
35/200 (18%) |
47/195 (24%) |
DAS28 ESR < /= 3.2 |
55/200 (28%) |
82/195 (42%) |
DAS28 CRP < 2.6 |
59/195 (30%) |
80/194 (41%) |
DAS28 CRP < /= 3.2 |
93/195 (48%) |
116/194 (60%) |
Boolean Remission |
19/195 (10%) |
32/194 (16%) |
Safety Results
Safety signals observed during the open-label extension were consistent with previously reported results of baricitinib. Among patients who remained on the 4 mg dose, treatment-emergent adverse events (TEAEs) occurred in 57 (53 percent); serious adverse events (SAEs) in 11 (10 percent); infections in 34 (31 percent); and serious infections in four (4 percent). Among patients who received the 8 mg dose, TEAEs occurred in 59 (63 percent); SAEs in eight (9 percent); infections in 37 (40 percent); and serious infections in two (2 percent). No opportunistic infections or tuberculosis cases were observed. There was one death in the 8 mg group due to a suspected myocardial infarction.
"In this clinical trial baricitinib showed statistically and clinically significant improvements in the features of this condition, which were maintained throughout a year of treatment. To date, baricitinib has demonstrated an acceptable safety profile and side effects have generally been straightforward to manage. These encouraging findings support further investigation of this new drug in rheumatoid arthritis," said
A copy of the EULAR oral presentation can be accessed at: 2013 EULAR -
Trial Design
This randomized, open-label, long-term extension of Phase 2b
In the initial 12-week treatment duration, patients received one of four doses of baricitinib (1 mg, 2 mg, 4 mg or 8 mg) or placebo, administered once daily. In the 12- to 24-week portion of the study, patients initially randomized to placebo or the 1 mg baricitinib dose were re-randomized to receive either 4 mg once daily or 2 mg twice daily for an additional 12 weeks; patients initially randomized to the 2 mg, 4 mg and 8 mg doses continued therapy with those doses.
Patients who completed week 24 were eligible to receive either the 4- or 8-mg once daily dose through week 52. The study is ongoing, with all patients who are continuing in the study receiving baricitinib 4 mg once daily.
About JAK Inhibition
There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.[3] These enzymes are critical components of signaling mechanisms used by a number of cytokines and growth factors, including several that are elevated in patients with RA. Cytokines such as interleukin-6, -12 and -23 and both type 1 and type 2 interferons signal through these pathways. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases, suggesting that JAK inhibitors may be useful for the treatment of a broad range of inflammatory conditions.
About Baricitinib
Baricitinib is an orally administered selective JAK1 and JAK2 inhibitor. Baricitinib is in Phase III development as a potential treatment for rheumatoid arthritis. It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy.
In
About Rheumatoid Arthritis
Rheumatoid arthritis is an autoimmune disease that is characterized by inflammation and progressive destruction of joints.[4] Current treatment of RA includes the use of non-steroidal anti-inflammatory drugs, oral disease-modifying antirheumatic drugs such as methotrexate, and injectable biological response modifiers that target selected mediators implicated in the pathogenesis of RA.[5]
About
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in
About
This press release contains certain forward-looking statements about baricitinib as a potential treatment for patients with rheumatoid arthritis and reflects Lilly and
P-LLY
[1] E. Keystone,
[2] M Genovese, E Keystone, P Taylor, P-Y Berclaz, C Lee, D Schlichting, S Beattie, M Luchi, W Macias. 24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral janus kinase 1/ janus kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2012; 64(10(supp)):S1049.
[3] S. Verstovsek. Therapeutic potential of JAK2 inhibitors.
[4]
[5]
Contacts:
Lilly:
Media:
Investors:
Media and Investors:
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)
(Logo: http://photos.prnewswire.com/prnh/20120608/DE21226LOGO)
SOURCE
News Provided by Acquire Media